Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Core Insights - Tango Therapeutics, Inc. announced that five abstracts have been accepted for poster presentations at the AACR Annual Meeting 2025, highlighting the company's commitment to advancing precision cancer medicines [1][2] Abstracts Accepted for Presentation - The first abstract focuses on the preclinical evaluation of CNS drug penetration of a novel series of MTAP-selective PRMT5 inhibitors, including TNG456, scheduled for presentation on April 27, 2025 [3] - The second abstract discusses TNG456 as a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for treating solid tumors with MTAP loss, also set for April 27, 2025 [3] - The third abstract presents TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrating strong efficacy in combination with targeted therapies in MTAP-null preclinical models, scheduled for April 28, 2025 [4] - The fourth abstract evaluates the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors, to be presented on April 29, 2025 [4] - The fifth abstract covers the genetic and pharmacological disruption of the HBS1L/PELO complex, leading to tumor regressions in FOCAD-deleted cancers, also scheduled for April 29, 2025 [5] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and delivering precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [5]